Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HER2-specific chimeric antigen receptor T cells + CAdVEC
- Development stage
- Unknown
- Lead developer
- Baylor College of Medicine
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous, Intratumoral
01
Overview
HER2-specific chimeric antigen receptor T cells + CAdVEC is an investigational combination immuno-oncology regimen developed by Baylor College of Medicine for advanced HER2-positive solid tumors. The therapy combines autologous T cells genetically engineered to express a chimeric antigen receptor targeting human epidermal growth factor receptor 2 with CAdVEC, a binary oncolytic and helper-dependent adenoviral platform intended to remodel the tumor microenvironment. The CAR-T component is designed to recognize and kill HER2-expressing tumor cells, while the adenoviral component is intended to enhance local immune activation, improve CAR-T-cell trafficking and persistence, and augment antitumor activity in solid tumors where adoptive cell therapy alone may be less effective.
- Other names
- HER2-directed chimeric antigen receptor T-cell therapy + oncolytic virusHER2-CAR-T cells + CAdVECHER2-specific chimeric antigen receptor T cells + binary oncolytic/helper-dependent adenovirusHER2 CAR-T cells + CAdVEC
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on HER2-specific chimeric antigen receptor T cells + CAdVEC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HER2-specific chimeric antigen receptor T cells + CAdVEC.